Objective:

To explore the evolving landscape of drug development in the post-COVID era, focusing on funding models, investor expectations, and innovative approaches.

Approach:

• Current Landscape Overview: Discussion on the evolution of drug development post-COVID, highlighting the adoption of decentralized trials, regulatory flexibility, and innovative approaches.
• Funding Model Changes: Analysis of how funding models and investor expectations have shifted, emphasizing the need for early clinical signals and global competition.

Key Findings:

• Early human data has become a critical value inflection point in drug development.
• The drug development landscape is becoming more innovative and fragmented.
• Geographic distribution of drug development is shifting towards a multipolar ecosystem.
• Funding models have changed, with increased emphasis on collaborative risk-sharing and global market strategies.

Interpretation:

Limitations:

• The article does not provide specific data on the success rates of new funding models.
• Future projections are speculative and may not accurately reflect actual developments.

Conclusion:

Sources:

• Nature Biotechnology